Mochida Pharmaceutical said on March 6 that it will codevelop Fuji Yakuhin’s investigational gout and hyperuricemia treatment FYU-981.FYU-981 stimulates the discharge of uric acid and has a different mechanism of action from that for the xanthine oxidase inhibitor Topiloric (topiroxostat),…
To read the full story
Related Article
- Fuji Yakuhin Files Hyperuricemia Candidate Dotinurad
December 26, 2018
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





